177 filings
Page 3 of 9
6-K
MDNAF
Medicenna Therapeutics Corp.
14 Aug 23
Medicenna Establishes Boston Presence, Appoints Brent Meadows as Chief Business Officer, and Bolsters Management
4:02pm
6-K
MDNAF
Medicenna Therapeutics Corp.
9 Aug 23
Medicenna Completes MDNA11 Dose Escalation and Commences Monotherapy Dose Expansion in the Phase 1/2 ABILITY Study
5:03pm
6-K
MDNAF
Medicenna Therapeutics Corp.
8 Aug 23
Medicenna Appoints Dr. Arash Yavari as Chair of Development Advisory Committee
9:36am
6-K
MDNAF
Medicenna Therapeutics Corp.
4 Aug 23
Current report (foreign)
8:40am
6-K
MDNAF
Medicenna Therapeutics Corp.
1 Aug 23
Medicenna Strengthens IP Portfolio with U.S. Patent Granted for the Use of Interleukin-2 Superkine Fusion Proteins in Oncology
12:01pm
6-K
MDNAF
Medicenna Therapeutics Corp.
28 Jul 23
Interim condensed consolidated financial statements of
8:31am
6-K
MDNAF
Medicenna Therapeutics Corp.
25 Jul 23
Medicenna Presents at National Brain Tumor Society's Research Round Table
8:00am
6-K
MDNAF
Medicenna Therapeutics Corp.
6 Jul 23
Current report (foreign)
10:32am
6-K
MDNAF
Medicenna Therapeutics Corp.
27 Jun 23
Medicenna Reports Fiscal Year 2023 Financial Results and Operational Highlights
2:35pm
6-K
MDNAF
Medicenna Therapeutics Corp.
27 Apr 23
Medicenna Granted 180-Day Extension to Meet Nasdaq Minimum Bid Price Requirement
11:10am
6-K
MDNAF
Medicenna Therapeutics Corp.
18 Apr 23
Medicenna to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference
7:30am
6-K
MDNAF
Medicenna Therapeutics Corp.
17 Apr 23
Medicenna Presents Preclinical IL-13 Superkine Data at the AACR Annual Meeting
4:23pm
6-K
MDNAF
Medicenna Therapeutics Corp.
30 Mar 23
Medicenna Provides Clinical Update from Monotherapy Dose Escalation Portion of Phase 1/2 ABILITY Study
7:15am
6-K
MDNAF
Medicenna Therapeutics Corp.
15 Mar 23
Medicenna Announces Upcoming Presentation at the AACR Annual Meeting
7:30am
6-K
MDNAF
Medicenna Therapeutics Corp.
2 Mar 23
Medicenna to Present at the Oppenheimer 33rd Annual Healthcare Conference
9:17am
EFFECT
MDNAF
Medicenna Therapeutics Corp.
28 Feb 23
Notice of effectiveness
12:15am
CORRESP
MDNAF
Medicenna Therapeutics Corp.
23 Feb 23
Correspondence with SEC
12:00am
UPLOAD
MDNAF
Medicenna Therapeutics Corp.
22 Feb 23
Letter from SEC
12:00am
6-K
MDNAF
Medicenna Therapeutics Corp.
17 Feb 23
Current report (foreign)
5:30pm